title: Unprotected left main stenting with a second-generation drug-eluting stent: one-year outcomes of the LEMAX Pilot study.
abstract: OBJECTIVE
  We sought to assess the efficacy and safety of everolimus-eluting stents for unprotected left main disease.
  
  
  RESULTS
  A total of 173 consecutive patients with de novo significant unprotected left main stenosis received an everolimus-eluting stent in four French centres. Among them, 140 (81 %) had involvement of the distal portion of left main, and 129/140 (92%) were treated with provisional side branch T-stenting, with a side branch stenting rate of 20%. Angiographic success was achieved in all cases. At 12 months, the cumulative rate of major adverse cardiac or cerebrovascular events (MACCE) was 26/173 (15%) including death from any cause (N=5, 2.9%), stroke (N=4, 2.3%), Q-wave myocardial infarction (MI) (N=2, 1.2%), non-Q-wave MI (N=6, 3.5%) and any repeat revascularisation (N=16, 9.3%). At one year, the rate of target-lesion revascularisation (TLR) was 5/173 (2.9%), target-vessel revascularisation was 12/173 (7 %) and the rate of definite or probable left main stent thrombosis 1/173 (0.6 %).
  
  
  CONCLUSIONS
  Unprotected left main stenting using everolimus-eluting stents and a strategy of provisional side branch T-stenting for distal lesions, is safe and effective in the midterm, with a relatively low rate of events and reintervention at one year.
authors: Institut Hospitalier Jacques Cartier, Massy, France.
authors: Neus
authors: N
authors: Salvatella
authors: Marie-Claude
authors: MC
authors: Morice
authors: Olivier
authors: O
authors: Darremont
authors: Muriel
authors: M
authors: Tafflet
authors: Philippe
authors: P
authors: Garot
authors: Jean Louis
authors: JL
authors: Leymarie
authors: Bernard
authors: B
authors: Chevalier
authors: Thierry
authors: T
authors: Lefèvre
authors: Yves
authors: Y
authors: Louvard
authors: Nicolas
authors: N
authors: Boudou
authors: Nicolas
authors: N
authors: Dumonteil
authors: Didier
authors: D
authors: Carrié
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000209:etiology; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D010865:Pilot Projects; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011474:Prosthesis Design; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D020521:Stroke / Q000209:etiology; D013927:Thrombosis / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D000068338:Everolimus; D020123:Sirolimus